Fluphenazine IM Injection

Form: Long-Acting Intramuscular Injection

Strength: 25 mg/mL

Reference Brands: Prolixin Decanoate(US); Fluphenazine Decanoate(EU)

Category: Antipsychotropic Drugs

Fluphenazine IM injection, available in both short-acting and long-acting (decanoate) formulations, is FDA-approved in the United States for the treatment of chronic schizophrenia. In the EU, it is approved in select markets under national procedures. Regulatory submissions must meet GMP standards, ensure accurate dosing for depot formulations, and include safety data addressing extrapyramidal symptoms and neuroleptic malignant syndrome. EU applications must align with local pharmacovigilance requirements and psychiatric labeling standards. For global buyers seeking dossier-ready Fluphenazine IM injections and to explore other dosage forms and suppliers, visit Pharmatradz.com — your reliable B2B pharma sourcing platform.